Objectives The aim of this study was to quantify the value of conducting additional research and reducing uncertainty regarding the cost effectiveness of allopurinol and febuxostat for the management of gout. Methods We used a previously developed Markov model that evaluated the cost effectiveness of nine urate-lowering strategies: no treatment, allopurinol-only fixed dose (300 mg), allopurinol-only dose escalation (up to 800 mg), febuxostat-only fixed dose (80 mg), febuxostat-only dose escalation (up to 120 mg), allopurinol-febuxostat sequential therapy fixed dose, allopurinol-febuxostat sequential therapy dose escalation, febuxostat-allopurinol sequential therapy fixed dose, and febuxostat-allopurinol sequential therapy dose escalation. Each strategy was evaluated over the lifetime of a hypothetical gout patient. We calculated population expected value of perfect information (EVPI). We used a linear regression meta-modeling approach to calculate population expected value of partial perfect information (EVPPI), and a Gaussian approximation to calculate the population expected value of sample information for parameters (EVSI) and the expected net benefit of sampling (ENBS) for four potential study designs: (1) an allopurinol efficacy trial; (2) a febuxostat efficacy trial; (3) a prospective observational study evaluating health utilities; and (4) a comprehensive study evaluating the efficacy of allopurinol and febuxostat and health utilities. A 5-year decision time horizon was used in the base-case analysis. Results EVPI varied by a decision maker's willingness-topay (WTP) per quality-adjusted life-year (QALY) and was $US900 million for WTP of $US60,000 per QALY. Population EVPPI was highest across all WTP values for study design #4. For study design #4 and a WTP of $US60,000 per QALY, the optimal sample size was 735 patients per study arm. Conclusions Future studies are needed to evaluate the effectiveness of allopurinol and febuxostat dose escalation.
Introduction
Gout is a common inflammatory arthritis that affects over 8 million adults in the United States [1] [2] [3] . It is associated with an increase in uric acid and results in debilitating acute attacks of severe pain [4, 5] . The American College of Rheumatology (ACR) clinical guidelines recommend urate-lowering therapy for established gout patients with tophi, two or more gout attacks per year, chronic kidney disease (Cstage 2), or past urolithiasis [2] . Both allopurinol and febuxostat are recommended by ACR as first-line urate-lowering treatment options [2] .
Allopurinol is the most commonly used urate-lowering therapy; it is well tolerated, inexpensive, and can be highly effective [2, [6] [7] [8] . Febuxostat, an alternative to allopurinol, was found in several clinical trials to be as safe as allopurinol and more effective in lowering serum uric acid [9] [10] [11] .
To help guide treatment decisions, in a prior analysis we developed a Markov decision model to evaluate the cost effectiveness of allopurinol and febuxostat [12] . In our prior analysis we found that allopurinol, when used with a dose-escalation strategy (up to 800 mg), was cost saving compared with no treatment. In addition, allopurinolfebuxostat sequential therapy dose escalation (i.e., patients start on allopurinol and only if they do not become controlled switch to febuxostat) was cost effective [incremental cost-effectiveness ratio (ICER) ranged from $US39,400 to $US68,800 (2012 US dollars) per qualityadjusted life-year (QALY)]. Dose-escalation febuxostatallopurinol was estimated to be the most effective and costly strategy but was not cost effective (ICER ranged from $US271,900 to $US563,800 per QALY).
To evaluate the cost effectiveness of allopurinol and febuxostat, our model incorporated evidence from clinical trials, epidemiologic studies, and clinical judgments. The model informs a decision given the best available information in the literature and plausible clinical assumptions. However, inherent in any model is uncertainty about the value of parameters (e.g., the effectiveness of allopurinol). The more uncertainty there is about the value of a parameter the greater the potential for choosing a suboptimal strategy. For example, there is a probability that allopurinol-febuxostat sequential therapy dose escalation may not truly be the most cost-effective strategy. In our prior analysis, we addressed uncertainty by conducting one-way, two-way, and probabilistic sensitivity analyses (PSAs). These methods provide a basis for understanding how the ICER and optimal strategy change when model inputs change based on current information on parameters of uncertainty [13] . These sensitivity analyses do not provide insight into the consequences of choosing a suboptimal strategy or the value of conducting additional research to reduce uncertainty.
Value of information (VOI) analysis provides a methodological framework for quantifying uncertainty and for evaluating the value of conducting additional research to reduce uncertainty. VOI analysis is increasingly being used by funders to inform the design and size of research studies and for prioritizing research portfolios [13] [14] [15] . A full VOI analysis takes into consideration the uncertainty of a model parameter set (e.g., uncertainty around the effectiveness of allopurinol), how reducing uncertainty will alter the decision (e.g., conclusions regarding the cost effectiveness of allopurinol-febuxostat sequential therapy dose escalation), and the cost of conducting additional research to reduce uncertainty. Until recently, conducting a full VOI analysis has imposed both methodological and computational challenges [16] [17] [18] .
In this study, we apply an enhanced linear regression meta-modeling approach to conduct a full VOI analysis to quantify decision uncertainty regarding the cost effectiveness of allopurinol and febuxostat for the management of gout [18, 19] . Specifically, we calculate the expected value of perfect information (EVPI), expected value of partial perfect information (EVPPI), and a Gaussian approximation of the Bayesian updating process to calculate the expected value of sample information for parameters (EVSI) and the expected net benefit of sampling (ENBS). We adjusted estimates to a population level accounting for the number of gout patients in the US that could potentially benefit from urate-lowering therapy. Finally, we provide funders and researchers with recommendations on the optimal designs of future research studies that could be conducted to reduce decision uncertainty regarding the cost effectiveness of allopurinol and febuxostat for the management of gout.
Methods

Model Details
In a prior Markov model, we evaluated the cost effectiveness of allopurinol and febuxostat for the management of gout in a hypothetical cohort of gout patients from the perspective of a US healthcare payer. The perspective of the payer varied based on the age of the cohort (\65 years, a private health insurance perspective and C65 years, a Medicare perspective). The model has been described in detail elsewhere [12] . In short, the model projected lifetime costs and QALYs for the following nine strategies: no treatment, allopurinol-only fixed dose (300 mg), allopurinol-only dose escalation (up to 800 mg), febuxostat-only fixed dose (80 mg), febuxostat-only dose escalation (up to 120 mg), allopurinol-febuxostat sequential therapy fixed dose, allopurinol-febuxostat sequential therapy dose escalation, febuxostat-allopurinol sequential therapy fixed dose, and febuxostat-allopurinol sequential therapy dose escalation. Within each strategy, hypothetical patients entered the simulation with uncontrolled gout (serum uric acid C360 lmol/L) [eFig. 1, see Electronic Supplementary Material (ESM)]. From this initial state, patients could remain uncontrolled, become controlled (serum uric acid \360 lmol/L), discontinue therapy, or die. Hypothetical patients in a sequential therapy strategy (e.g., allopurinolfebuxostat sequential therapy) could switch medications if they were uncontrolled on first-line therapy.
In our original study, we conducted extensive sensitivity analyses on key structural assumptions (e.g., reducing the effect of second-line therapy). In this analysis, we incorporated key structural assumptions to determine their contribution to decision uncertainty. However, we did not incorporate the structural assumption that allowed controlled patients on medication to become uncontrolled (i.e., treatment was effective in reducing serum uric acid but then became ineffective) as results from clinical trials indicate this scenario is highly unlikely [10, 11, 20] . Table 1 details the model parameters, their point estimates, and the distributions used to characterize uncertainty. Model parameters for treatment effectiveness, adverse events, health-related quality of life, and costs were derived from the literature. Clinical assumptions were made regarding the probability of switching therapy (in sequential therapy options) and discontinuing treatment due to therapeutic failure. Probability and utility parameters derived from the literature were assigned beta distributions, and costs were assigned gamma distributions. Uniform distributions were used when limited data were available. All model parameters were assumed to be independent.
Value of Information Analysis
We used an enhanced linear regression meta-modeling approach to conduct a full VOI analysis [19] . This enhanced meta-modeling approach relaxes the previous linear regression meta-modeling assumptions of net benefit normality and model linearity [18] . All costs in the current analysis are reported in 2013 US dollars, which is consistent with our prior study reporting results from the Markov model.
Probabilistic Sensitivity Analysis
The first step of the linear regression meta-modeling approach consisted of evaluating the model using a PSA. The resulting PSA dataset contained 10,000 rows-a row per simulation, consisting of the value of each model parameter and the expected costs and QALYs associated with each strategy (eData 1, see ESM).
Expected Value of Individual and Population Perfect Information
EVPI represents the maximum a decision maker should be willing to pay (WTP) to eliminate uncertainty from all the parameters. We used the PSA dataset and the algorithm reported by Briggs et al. to calculate EVPI [13] . First, we calculated the net monetary benefits (net monetary benefits = QALY 9 WTP -cost) of each strategy over a range of WTP values ($US0-$US400,000). Second, we identified the overall optimal strategy at each WTP value. The overall optimal strategy has the highest expected net monetary benefit across all simulations (each simulation is represented by a row in the PSA dataset). Third, we identified simulations (i.e., rows in the PSA dataset) in which the optimal choice differed from the overall optimal strategy. This difference represents the opportunity loss, and we averaged the opportunity loss across all simulations to calculate EVPI [13, 21, 22] . We extrapolated EVPI from an individual-to a population-level estimate based on the total number of patients that could benefit from treatment over a 5-year decision lifetime [13, 23] . A 5-year decision lifetime was adopted as this corresponds with when generic versions of febuxostat may become available based on the expiration of key patents [24] . Approximately 30% of current US prevalent gout cases (n = 8,300,000 9 0.30) and 30% of incident gout cases (annual incident cases n = 199,360 9 0.30) were assumed to be candidates for urate-lowering therapy [1, [25] [26] [27] [28] . The benefit of information from additional research was discounted by 3% [13] .
Expected Value of Individual and Population Partial
Perfect Information EVPPI provides an estimate of the value of eliminating uncertainty for specific parameters (e.g., the effectiveness of allopurinol) or groups of parameters. We used the metamodeling approach to calculate EVPPI for each parameter. This consisted of regressing the opportunity loss of each strategy (identified when calculating EVPI) on each model parameter [18, 19] . We extrapolated EVPPI on a population level assuming a 5-year decision lifetime. We also calculated EVPPI and population EVPPI for groups of parameters that could be evaluated together in future research designs. We hypothesized that four distinct research studies could be conducted to collect additional information on key model parameters (eTable 1, see ESM). First, a randomized Value of Information Analysis for Research on Urate-Lowering Therapiescontrolled trial could be conducted to evaluate the efficacy of allopurinol dose escalation when it is implemented as part of a sequential therapy strategy (study design #1). Second, a randomized controlled trial could be conducted to evaluate the efficacy of febuxostat dose escalation when it is implemented as part of a sequential therapy strategy (study design #2). These efficacy studies would also evaluate all ancillary outcomes including the probability of adverse events, probability of having a flare, probability of stopping treatment, and mean time spent on treatment prior to stopping. Third, a prospective observational study could be conducted to evaluate the health utility of gout patients (study design #3). Specifically, this study would inform the health utility assigned to the model states of being controlled, uncontrolled on treatment, uncontrolled off treatment, and the disutility associated with flares and adverse events. Finally, a comprehensive randomized controlled trial could be conducted to evaluate the efficacy of allopurinol dose escalation when it is implemented as part of a sequential therapy strategy, febuxostat dose escalation when it is implemented as part of a sequential therapy strategy, ancillary outcomes, and the health utilities of gout patients (study design #4). We assumed the duration of these future studies was 1 year, which is consistent with the key trials used to inform the model inputs [10, 29] .
Expected Value of Sample Information for Parameters
EVSI represents the value gained, or alternatively the amount of uncertainty reduced, from a research study with a given sample size (n). We used a combination of metamodeling and Gaussian approximation to calculate EVSI for each proposed study design (eTable 1, see ESM).
Specifically, we applied a parameter-specific variance reduction factor [18, 19, 30, 31] . The variance reduction factor takes account of the sample size that was used to inform the specific model parameter (i.e., the prior sample size) and the sample size of future research studies. Finally, we extrapolated EVSI to a population level. NA not applicable
Expected Net Benefit of Sampling and the Optimal Sample Size
ENBS provides an estimate of the marginal benefit of acquiring information from an additional sample of a research study given population EVSI and the cost of collecting data plus the opportunity cost associated with not receiving the most cost-effective treatment during the duration of the proposed 1-year trial. ENBS for the future observational study did not include an opportunity cost associated with receiving an inferior treatment as patients are not assigned treatment in the proposed observational study design. The optimal sample size (n*) of a future study is the sample size that maximizes the difference between EVSI and the cost of conducting the study (i.e., the ENBS). We calculated ENBS and n* for the four hypothetical study designs (eTable 1, see ESM). A decision maker prioritizing among the four competing research designs should select the proposed study with the highest ENBS [13] . The data collection cost depends on the study design (e.g., randomized controlled trial or prospective observational study). We estimated the cost of conducting a trial using data from several sources. First, we relied on data from a study that reported funding by the US National Institute of Neurological Disorders and Stroke for 27 randomized controlled trials [32] . Second, we used data from a study that reported the per-patient cost of including an individual in a clinical trial [33] . Using these data sources, we separated the total cost of a trial into fixed and variable costs. Based on these data, we estimated that a randomized controlled trial had a fixed cost of $US8,740,000 and a cost per patient of $US8440 (eTable 1, see ESM). The cost of conducting a prospective observational study was less than that of a randomized controlled trial and was assumed to have a fixed cost of $US50,000 [US$40,000 for a full-time research assistant plus US$10,000 (10% time) for an assistant professor] and a cost per patient of US$500 (mail-based survey with participants identified from an outpatient rheumatology clinic).
Statistical and Sensitivity Analyses
We conducted extensive sensitivity analyses in which we evaluated n* for each study design under the assumption of ) shows the cost-effectiveness acceptability curve for all strategies. QALY quality-adjusted life-years a 3-and 10-year decision lifetime, varied the number of current prevalent and future incident cases (±50% of base case), and varied the fixed and per-patient cost of collecting data (±50% of base case). The Markov model was constructed using TreeAge Pro 2014 (TreeAge Software). The VOI analysis was done in R [18, 19] .
Results
Probabilistic Sensitivity Analysis
Results from our analysis indicate that allopurinol-only dose escalation was cost saving compared with no treatment (eTable 2, see ESM). Compared with allopurinolonly dose escalation, allopurinol-febuxostat sequential therapy dose escalation was costlier and more effective and had an ICER of $US59,000 per QALY. Febuxostat-allopurinol sequential therapy dose escalation was costlier and more effective than allopurinol-febuxostat sequential therapy dose escalation and had an ICER of $US332,300 per QALY. All other strategies were dominated. These ICERs differ slightly from those in our original study because we reran the PSA and included key structural assumptions [12] . Nevertheless, overall conclusions remained consistent. The cost-effectiveness acceptability curve (CEAC) shows the urate-lowering strategy with the highest probability of being cost effective given a decision maker's WTP [ Fig. 1 shows CEAC for dominant strategies; eFig. 2 (see ESM) shows CEAC for all strategies]. With a WTP of between $US0 and $US60,000 per QALY, allopurinol-only dose escalation has the highest probability of being cost effective. As the WTP threshold approaches $US60,000 per QALY, the probability of allopurinol-only dose escalation being cost effective decreases reflecting greater uncertainty regarding the strategy with the highest probability of being cost effective. Between a WTP of $US60,000 and $US360,000 per QALY, allopurinol-febuxostat sequential therapy dose escalation has the highest probability of being cost effective.
Expected Value of Individual and Population Perfect Information
Population EVPI increases when there is greater uncertainty regarding the most cost-effective strategy [ . EVPI peaks at the WTP thresholds where the decision changes (i.e., ICER). As the opportunity loss increases, there is greater value in eliminating uncertainty. For example, when WTP was $US60,000 per QALY, EVPI was $US900 million. In contrast, when WTP was $US20,000 per QALY, EVPI was only $US90 million. The difference in EVPI between WTP values reflects the amount of uncertainty regarding the optimal strategy. Finally, due to the non-symmetric distribution of the incremental net benefit, the peaks in EVPI do not perfectly correspond with the WTP thresholds where the strategies cross on the CEAC.
Expected Value of Individual and Population Partial Perfect Information
EVPPI and population EVPPI were highest at all WTP values for allopurinol and febuxostat dose escalation efficacy parameters (parameter-specific EVPPI are not shown). Population EVPPI for the groups of parameters to be evaluated in each study design increases when there is greater uncertainty regarding the most cost-effective strategy [ Fig. 3 ; eFig. 4 (see ESM) shows individual level EVPPI]. At all WTP values, population EVPPI was greatest for the set of parameters in the study evaluating allopurinol dose escalation, febuxostat dose escalation, and utilities (study design #4). For example, at a WTP of $US60,000 per QALY, population EVPPI for the parameters evaluated in study design #4 was $US600 million.
Expected Value of Sample Information and Expected Net Benefit of Sampling
Population EVSI for several WTP thresholds for study design #4 are presented in Fig. 4 (eFigs 5-7 show population EVSI for study design #1-3, see ESM). Figure 4 also shows the cost of research given the proposed study design (randomized controlled trial) and ENBS. A positive ENBS indicates the value of conducting additional research outweighs the cost of collecting the data. The optimal sample size (n*) for study design #4, which had the highest ENBS across all study designs, was 735 patients per study arm given a WTP of $US60,000 per QALY. In sensitivity analyses, n* was sensitive to the cost of research and the size of the prevalent population that could 
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• study design #4 study design #1 study design #2 study design #3 Fig. 3 Population expected value of partial perfect information. Hypothetical study designs are presented in increasing value. Study design #1: RCT evaluating the efficacy of allopurinol dose escalation. Study design #2: RCT evaluating the efficacy of febuxostat dose escalation. Study design #3: a prospective observational study evaluating the health utility of gout patients. Study design #4: a comprehensive RCT evaluating the efficacy of allopurinol dose escalation, febuxostat dose escalation, ancillary outcomes, and the health utilities of gout patients. EVPPI expected value of partial perfect information, QALY quality-adjusted life-years, RCT randomized controlled trial benefit from treatment ( Table 2 ). The sensitivity of these inputs also depended on WTP. For example, given a WTP of $US60,000 per QALY, when both the fixed and perpatient cost of research varied by 50% of the base-case, n* for study design #4 varied between 1030 and 585 (basecase n* = 735). Similarly, when the number of prevalent cases that could benefit from treatment varied by 50% of the base-case value, n* for study design #4 varied between 500 and 920. n* was less sensitive to the decision lifetime and number of incident cases.
Discussion
We conducted a full VOI analysis to inform policymakers and researchers as to the potential value of funding additional research to reduce decision uncertainty on the cost effectiveness of allopurinol and febuxostat for the management of gout. We employed an enhanced linear regression meta-modeling approach that relaxes the restrictive assumptions of a previous linear regression meta-modeling approach [18, 19] . A unique feature of our study is the evaluation of EVPPI for groups of parameters that could be evaluated in a study (e.g., a randomized trial or observational study). This is a departure from prior VOI analyses that often evaluated EVPPI for conceptually similar parameters (e.g., transition probabilities, utilities, and costs). A key finding from our analysis is that additional research on the effectiveness of allopurinol and febuxostat and the health utility of gout patients is warranted. An important feature of our study is the evaluation of the optimal sample size of conducting additional research. We found that a well designed randomized trial evaluating allopurinol-only dose escalation (i.e., study design #1) should enroll 220 patients per study arm given a decision maker is WTP $US60,000 or $US100,000 per QALY. A trial evaluating allopurinol, febuxostat, and utilities in the same study should enroll 735 patients per study arm (i.e., study design #4). Our optimal sample sizes correspond with the sample sizes used in previous allopurinol and febuxostat efficacy trials. For example, a three-arm randomized controlled trial of fixed-dose febuxostat (80, 120 mg) and allopurinol (300 mg) assigned 762 patients across all arms, approximately 250 patients per arm [10] . Currently, recruitment is underway for a clinical trial comparing Fig. 4 Population expected value of sample information and expected net benefit of sampling to collect data on allopurinol dose escalation and febuxostat dose escalation (study design #4). ENBS expected net benefit of sampling, n* optimal sample size per arm of a two-arm trial given the popEVSI and the ENBS, popEVSI population expected value of sample information allopurinol and febuxostat, and the trial has a target sample size of 950 patients [34] . This sample size is slightly smaller than the optimal sample size we identified for study design #4 (762 per study arm). However, because information on the ongoing trial is limited (e.g., assumptions of power calculations), we were unable to evaluate exact reasons for differences in target sample sizes. VOI methods can be used to supplement traditional power calculations to help inform the design of clinical research [35] . Often, research studies are designed using power calculations and are planned to meet efficacy and safety requirements of regulatory agencies. However, power calculations have been criticized because they rely on subjective judgment to determine type I and type II errors; they do not take into consideration the contributions of prior research and they fail to account for the cost of conducting research [36] . Furthermore, the efficacy and safety requirements of regulatory agencies may be at odds with the data needs of funding agencies (e.g., cost-effectiveness data such as cost and health utilities). VOI methods can be used to inform the cost-effectiveness data that should be collected given limited research funds [37] . In addition, unlike power analyses, VOI can be used to inform research prioritization across clinical areas within funding agencies. That is, the value of additional research can be used to explicitly compare competing research proposals [35, 38, 39] . With recent methodological advances to compute VOI measures, the use of VOI analysis to inform research studies and prioritization should become more prominent. In addition to conducting traditional power calculations, clinical investigators should begin using VOI methods to inform the design of clinical studies. Importantly, VOI methods provide insight into the value of reducing uncertainty for model parameters and the efficiency of study designs. VOI does not provide an understanding of the value of innovation (e.g., the value of improving the efficacy of treatment), which is the role of economic evaluations. Results of our VOI analysis are specific to our study setting and population (US gout patients who may benefit from allopurinol or febuxostat). While we found there was value in conducting research in the US, research may not be beneficial in other countries with different WTP thresholds and research costs. Nevertheless, we reported results over a range of WTP values to inform decision makers with different thresholds. Finally, other countries may still benefit from the research conducted in the US.
Our study has several limitations. Foremost, EVSI and ENBS depend on accurately evaluating prior sample sizes and distributions. In addition, VOI analyses are dependent on the WTP threshold. Unlike in many European countries, in the US there is no generally accepted threshold. To overcome this limitation, we present results over a wide range of WTP values. Finally, VOI analysis depends on assumptions regarding the decision lifetime, the population that would benefit from treatment, and the cost of conducting research. We conducted extensive sensitivity analyses to test these assumptions.
Conclusion
In conclusion, we found there is value in conducting additional research on the effectiveness of allopurinol dose escalation and febuxostat dose escalation. Our study highlights the utility of using an enhanced linear regression meta-modeling approach with a Gaussian approximation to conduct a full VOI analysis to inform the design of future research studies.
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